{
    "title": "Recurrent subarachnoid hemorrhage associated with aminocaproic acid therapy and acute renal artery thrombosis. Case report.",
    "abst": "Epsilon aminocaproic acid (EACA) has been used to prevent rebleeding in patients with subarachnoid hemorrhage (SAH). Although this agent does decrease the frequency of rebleeding, several reports have described thrombotic complications of EACA therapy. These complications have included clinical deterioration and intracranial vascular thrombosis in patients with SAH, arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with EACA, or other thromboembolic phenomena. Since intravascular fibrin thrombi are often observed in patients with fibrinolytic disorders, EACA should not be implicated in the pathogenesis of fibrin thrombi in patients with disseminated intravascular coagulation or other \"consumption coagulopathies.\" This report describes subtotal infarction of the kidney due to thrombosis of a normal renal artery. This occlusion occurred after EACA therapy in a patient with SAH and histopathological documentation of recurrent SAH. The corresponding clinical event was characterized by marked hypertension and abrupt neurological deterioration.",
    "title_plus_abst": "Recurrent subarachnoid hemorrhage associated with aminocaproic acid therapy and acute renal artery thrombosis. Case report. Epsilon aminocaproic acid (EACA) has been used to prevent rebleeding in patients with subarachnoid hemorrhage (SAH). Although this agent does decrease the frequency of rebleeding, several reports have described thrombotic complications of EACA therapy. These complications have included clinical deterioration and intracranial vascular thrombosis in patients with SAH, arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with EACA, or other thromboembolic phenomena. Since intravascular fibrin thrombi are often observed in patients with fibrinolytic disorders, EACA should not be implicated in the pathogenesis of fibrin thrombi in patients with disseminated intravascular coagulation or other \"consumption coagulopathies.\" This report describes subtotal infarction of the kidney due to thrombosis of a normal renal artery. This occlusion occurred after EACA therapy in a patient with SAH and histopathological documentation of recurrent SAH. The corresponding clinical event was characterized by marked hypertension and abrupt neurological deterioration.",
    "pubmed_id": "448423",
    "entities": [
        [
            10,
            33,
            "subarachnoid hemorrhage",
            "Disease",
            "D013345"
        ],
        [
            50,
            67,
            "aminocaproic acid",
            "Chemical",
            "D000614"
        ],
        [
            80,
            109,
            "acute renal artery thrombosis",
            "Disease",
            "D007674"
        ],
        [
            124,
            149,
            "Epsilon aminocaproic acid",
            "Chemical",
            "D015119"
        ],
        [
            151,
            155,
            "EACA",
            "Chemical",
            "D015119"
        ],
        [
            210,
            233,
            "subarachnoid hemorrhage",
            "Disease",
            "D013345"
        ],
        [
            235,
            238,
            "SAH",
            "Disease",
            "D013345"
        ],
        [
            335,
            345,
            "thrombotic",
            "Disease",
            "D013927"
        ],
        [
            363,
            367,
            "EACA",
            "Chemical",
            "D015119"
        ],
        [
            438,
            470,
            "intracranial vascular thrombosis",
            "Disease",
            "D020767"
        ],
        [
            488,
            491,
            "SAH",
            "Disease",
            "D013345"
        ],
        [
            525,
            532,
            "thrombi",
            "Disease",
            "D013927"
        ],
        [
            586,
            590,
            "EACA",
            "Chemical",
            "D015119"
        ],
        [
            601,
            625,
            "thromboembolic phenomena",
            "Disease",
            "D013923"
        ],
        [
            654,
            661,
            "thrombi",
            "Disease",
            "D013927"
        ],
        [
            722,
            726,
            "EACA",
            "Chemical",
            "D015119"
        ],
        [
            782,
            789,
            "thrombi",
            "Disease",
            "D013927"
        ],
        [
            807,
            845,
            "disseminated intravascular coagulation",
            "Disease",
            "D004211"
        ],
        [
            856,
            882,
            "consumption coagulopathies",
            "Disease",
            "D004211"
        ],
        [
            916,
            926,
            "infarction",
            "Disease",
            "D007238"
        ],
        [
            948,
            983,
            "thrombosis of a normal renal artery",
            "Disease",
            "D007674"
        ],
        [
            1015,
            1019,
            "EACA",
            "Chemical",
            "D015119"
        ],
        [
            1046,
            1049,
            "SAH",
            "Disease",
            "D013345"
        ],
        [
            1099,
            1102,
            "SAH",
            "Disease",
            "D013345"
        ],
        [
            1165,
            1177,
            "hypertension",
            "Disease",
            "D006973"
        ]
    ],
    "split_sentence": [
        "Recurrent subarachnoid hemorrhage associated with aminocaproic acid therapy and acute renal artery thrombosis.",
        "Case report.",
        "Epsilon aminocaproic acid (EACA) has been used to prevent rebleeding in patients with subarachnoid hemorrhage (SAH).",
        "Although this agent does decrease the frequency of rebleeding, several reports have described thrombotic complications of EACA therapy.",
        "These complications have included clinical deterioration and intracranial vascular thrombosis in patients with SAH, arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with EACA, or other thromboembolic phenomena.",
        "Since intravascular fibrin thrombi are often observed in patients with fibrinolytic disorders, EACA should not be implicated in the pathogenesis of fibrin thrombi in patients with disseminated intravascular coagulation or other \"consumption coagulopathies.\" This report describes subtotal infarction of the kidney due to thrombosis of a normal renal artery.",
        "This occlusion occurred after EACA therapy in a patient with SAH and histopathological documentation of recurrent SAH.",
        "The corresponding clinical event was characterized by marked hypertension and abrupt neurological deterioration."
    ],
    "if_txt_length_is_changed_flag": 0,
    "lines": [
        "D013345\tDisease\tsubarachnoid hemorrhage\tRecurrent <target> subarachnoid hemorrhage </target> associated with aminocaproic acid therapy and acute renal artery thrombosis .",
        "D000614\tChemical\taminocaproic acid\tRecurrent subarachnoid hemorrhage associated with <target> aminocaproic acid </target> therapy and acute renal artery thrombosis .",
        "D007674\tDisease\tacute renal artery thrombosis\tRecurrent subarachnoid hemorrhage associated with aminocaproic acid therapy and <target> acute renal artery thrombosis </target> .",
        "D015119\tChemical\tEpsilon aminocaproic acid\t<target> Epsilon aminocaproic acid </target> ( EACA ) has been used to prevent rebleeding in patients with subarachnoid hemorrhage ( SAH ) .",
        "D015119\tChemical\tEACA\tEpsilon aminocaproic acid ( <target> EACA </target> ) has been used to prevent rebleeding in patients with subarachnoid hemorrhage ( SAH ) .",
        "D013345\tDisease\tsubarachnoid hemorrhage\tEpsilon aminocaproic acid ( EACA ) has been used to prevent rebleeding in patients with <target> subarachnoid hemorrhage </target> ( SAH ) .",
        "D013345\tDisease\tSAH\tEpsilon aminocaproic acid ( EACA ) has been used to prevent rebleeding in patients with subarachnoid hemorrhage ( <target> SAH </target> ) .",
        "D013927\tDisease\tthrombotic\tAlthough this agent does decrease the frequency of rebleeding , several reports have described <target> thrombotic </target> complications of EACA therapy .",
        "D015119\tChemical\tEACA\tAlthough this agent does decrease the frequency of rebleeding , several reports have described thrombotic complications of <target> EACA </target> therapy .",
        "D020767\tDisease\tintracranial vascular thrombosis\tThese complications have included clinical deterioration and <target> intracranial vascular thrombosis </target> in patients with SAH , arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with EACA , or other thromboembolic phenomena .",
        "D013345\tDisease\tSAH\tThese complications have included clinical deterioration and intracranial vascular thrombosis in patients with <target> SAH </target> , arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with EACA , or other thromboembolic phenomena .",
        "D013927\tDisease\tthrombi\tThese complications have included clinical deterioration and intracranial vascular thrombosis in patients with SAH , arteriolar and capillary fibrin <target> thrombi </target> in patients with fibrinolytic syndromes treated with EACA , or other thromboembolic phenomena .",
        "D015119\tChemical\tEACA\tThese complications have included clinical deterioration and intracranial vascular thrombosis in patients with SAH , arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with <target> EACA </target> , or other thromboembolic phenomena .",
        "D013923\tDisease\tthromboembolic phenomena\tThese complications have included clinical deterioration and intracranial vascular thrombosis in patients with SAH , arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with EACA , or other <target> thromboembolic phenomena </target> .",
        "D013927\tDisease\tthrombi\tSince intravascular fibrin <target> thrombi </target> are often observed in patients with fibrinolytic disorders , EACA should not be implicated in the pathogenesis of fibrin thrombi in patients with disseminated intravascular coagulation or other \" consumption coagulopathies . \" This report describes subtotal infarction of the kidney due to thrombosis of a normal renal artery .",
        "D015119\tChemical\tEACA\tSince intravascular fibrin thrombi are often observed in patients with fibrinolytic disorders , <target> EACA </target> should not be implicated in the pathogenesis of fibrin thrombi in patients with disseminated intravascular coagulation or other \" consumption coagulopathies . \" This report describes subtotal infarction of the kidney due to thrombosis of a normal renal artery .",
        "D013927\tDisease\tthrombi\tSince intravascular fibrin thrombi are often observed in patients with fibrinolytic disorders , EACA should not be implicated in the pathogenesis of fibrin <target> thrombi </target> in patients with disseminated intravascular coagulation or other \" consumption coagulopathies . \" This report describes subtotal infarction of the kidney due to thrombosis of a normal renal artery .",
        "D004211\tDisease\tdisseminated intravascular coagulation\tSince intravascular fibrin thrombi are often observed in patients with fibrinolytic disorders , EACA should not be implicated in the pathogenesis of fibrin thrombi in patients with <target> disseminated intravascular coagulation </target> or other \" consumption coagulopathies . \" This report describes subtotal infarction of the kidney due to thrombosis of a normal renal artery .",
        "D004211\tDisease\tconsumption coagulopathies\tSince intravascular fibrin thrombi are often observed in patients with fibrinolytic disorders , EACA should not be implicated in the pathogenesis of fibrin thrombi in patients with disseminated intravascular coagulation or other \" <target> consumption coagulopathies </target> . \" This report describes subtotal infarction of the kidney due to thrombosis of a normal renal artery .",
        "D007238\tDisease\tinfarction\tSince intravascular fibrin thrombi are often observed in patients with fibrinolytic disorders , EACA should not be implicated in the pathogenesis of fibrin thrombi in patients with disseminated intravascular coagulation or other \" consumption coagulopathies . \" This report describes subtotal <target> infarction </target> of the kidney due to thrombosis of a normal renal artery .",
        "D007674\tDisease\tthrombosis of a normal renal artery\tSince intravascular fibrin thrombi are often observed in patients with fibrinolytic disorders , EACA should not be implicated in the pathogenesis of fibrin thrombi in patients with disseminated intravascular coagulation or other \" consumption coagulopathies . \" This report describes subtotal infarction of the kidney due to <target> thrombosis of a normal renal artery </target> .",
        "D015119\tChemical\tEACA\tThis occlusion occurred after <target> EACA </target> therapy in a patient with SAH and histopathological documentation of recurrent SAH .",
        "D013345\tDisease\tSAH\tThis occlusion occurred after EACA therapy in a patient with <target> SAH </target> and histopathological documentation of recurrent SAH .",
        "D013345\tDisease\tSAH\tThis occlusion occurred after EACA therapy in a patient with SAH and histopathological documentation of recurrent <target> SAH </target> .",
        "D006973\tDisease\thypertension\tThe corresponding clinical event was characterized by marked <target> hypertension </target> and abrupt neurological deterioration ."
    ],
    "lines_lemma": [
        "D013345\tDisease\tsubarachnoid hemorrhage\tRecurrent <target> subarachnoid hemorrhage </target> associate with aminocaproic acid therapy and acute renal artery thrombosis .",
        "D000614\tChemical\taminocaproic acid\trecurrent subarachnoid hemorrhage associate with <target> aminocaproic acid </target> therapy and acute renal artery thrombosis .",
        "D007674\tDisease\tacute renal artery thrombosis\trecurrent subarachnoid hemorrhage associate with aminocaproic acid therapy and <target> acute renal artery thrombosis </target> .",
        "D015119\tChemical\tEpsilon aminocaproic acid\t<target> epsilon aminocaproic acid </target> ( eaca ) have be use to prevent rebleeding in patient with subarachnoid hemorrhage ( sah ) .",
        "D015119\tChemical\tEACA\tepsilon aminocaproic acid ( <target> eaca </target> ) have be use to prevent rebleeding in patient with subarachnoid hemorrhage ( sah ) .",
        "D013345\tDisease\tsubarachnoid hemorrhage\tepsilon aminocaproic acid ( eaca ) have be use to prevent rebleeding in patient with <target> subarachnoid hemorrhage </target> ( sah ) .",
        "D013345\tDisease\tSAH\tepsilon aminocaproic acid ( eaca ) have be use to prevent rebleeding in patient with subarachnoid hemorrhage ( <target> sah </target> ) .",
        "D013927\tDisease\tthrombotic\talthough this agent do decrease the frequency of rebleeding , several report have describe <target> thrombotic </target> complication of eaca therapy .",
        "D015119\tChemical\tEACA\talthough this agent do decrease the frequency of rebleeding , several report have describe thrombotic complication of <target> eaca </target> therapy .",
        "D020767\tDisease\tintracranial vascular thrombosis\tthese complication have include clinical deterioration and <target> intracranial vascular thrombosis </target> in patient with sah , arteriolar and capillary fibrin thrombi in patient with fibrinolytic syndrome treat with eaca , or other thromboembolic phenomenon .",
        "D013345\tDisease\tSAH\tthese complication have include clinical deterioration and intracranial vascular thrombosis in patient with <target> sah </target> , arteriolar and capillary fibrin thrombi in patient with fibrinolytic syndrome treat with eaca , or other thromboembolic phenomenon .",
        "D013927\tDisease\tthrombi\tthese complication have include clinical deterioration and intracranial vascular thrombosis in patient with sah , arteriolar and capillary fibrin <target> thrombi </target> in patient with fibrinolytic syndrome treat with eaca , or other thromboembolic phenomenon .",
        "D015119\tChemical\tEACA\tthese complication have include clinical deterioration and intracranial vascular thrombosis in patient with sah , arteriolar and capillary fibrin thrombi in patient with fibrinolytic syndrome treat with <target> eaca </target> , or other thromboembolic phenomenon .",
        "D013923\tDisease\tthromboembolic phenomena\tthese complication have include clinical deterioration and intracranial vascular thrombosis in patient with sah , arteriolar and capillary fibrin thrombi in patient with fibrinolytic syndrome treat with eaca , or other <target> thromboembolic phenomenon </target> .",
        "D013927\tDisease\tthrombi\tsince intravascular fibrin <target> thrombi </target> be often observe in patient with fibrinolytic disorder , eaca should not be implicate in the pathogenesis of fibrin thrombi in patient with disseminate intravascular coagulation or other \" consumption coagulopathie . \" this report describe subtotal infarction of the kidney due to thrombosis of a normal renal artery .",
        "D015119\tChemical\tEACA\tsince intravascular fibrin thrombi be often observe in patient with fibrinolytic disorder , <target> eaca </target> should not be implicate in the pathogenesis of fibrin thrombi in patient with disseminate intravascular coagulation or other \" consumption coagulopathie . \" this report describe subtotal infarction of the kidney due to thrombosis of a normal renal artery .",
        "D013927\tDisease\tthrombi\tsince intravascular fibrin thrombi be often observe in patient with fibrinolytic disorder , eaca should not be implicate in the pathogenesis of fibrin <target> thrombi </target> in patient with disseminate intravascular coagulation or other \" consumption coagulopathie . \" this report describe subtotal infarction of the kidney due to thrombosis of a normal renal artery .",
        "D004211\tDisease\tdisseminated intravascular coagulation\tsince intravascular fibrin thrombi be often observe in patient with fibrinolytic disorder , eaca should not be implicate in the pathogenesis of fibrin thrombi in patient with <target> disseminated intravascular coagulation </target> or other \" consumption coagulopathie . \" this report describe subtotal infarction of the kidney due to thrombosis of a normal renal artery .",
        "D004211\tDisease\tconsumption coagulopathies\tsince intravascular fibrin thrombi be often observe in patient with fibrinolytic disorder , eaca should not be implicate in the pathogenesis of fibrin thrombi in patient with disseminate intravascular coagulation or other \" <target> consumption coagulopathie </target> . \" this report describe subtotal infarction of the kidney due to thrombosis of a normal renal artery .",
        "D007238\tDisease\tinfarction\tsince intravascular fibrin thrombi be often observe in patient with fibrinolytic disorder , eaca should not be implicate in the pathogenesis of fibrin thrombi in patient with disseminate intravascular coagulation or other \" consumption coagulopathie . \" this report describe subtotal <target> infarction </target> of the kidney due to thrombosis of a normal renal artery .",
        "D007674\tDisease\tthrombosis of a normal renal artery\tsince intravascular fibrin thrombi be often observe in patient with fibrinolytic disorder , eaca should not be implicate in the pathogenesis of fibrin thrombi in patient with disseminate intravascular coagulation or other \" consumption coagulopathie . \" this report describe subtotal infarction of the kidney due to <target> thrombosis of a normal renal artery </target> .",
        "D015119\tChemical\tEACA\tthis occlusion occur after <target> eaca </target> therapy in a patient with sah and histopathological documentation of recurrent sah .",
        "D013345\tDisease\tSAH\tthis occlusion occur after eaca therapy in a patient with <target> sah </target> and histopathological documentation of recurrent sah .",
        "D013345\tDisease\tSAH\tthis occlusion occur after eaca therapy in a patient with sah and histopathological documentation of recurrent <target> sah </target> .",
        "D006973\tDisease\thypertension\tthe corresponding clinical event be characterize by marked <target> hypertension </target> and abrupt neurological deterioration ."
    ]
}